Tumor Antigen-specific T Cells
Tumor Antigen-specific T Cells - Related Videos
04:42
An Ex Vivo Technique to Generate Tumor-Specific Chimeric Antigen Receptor T Cells
0 Views •
2025
This video demonstrates a technique for the ex vivo generation of tumor antigen-specific chimeric antigen receptor (CAR) T cells. Retroviral vectors carrying transgenic RNA are mixed with spleen cells in a medium supplemented with interleukin-2 to promote T-cell survival and proliferation. The mixture is then transferred to a plate coated with recombinant human fibronectin fragments and centrifuged to facilitate the fusion of the virus with the cell, allowing the RNA to integrate into the host...
10:57
Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells
0 Views •
Cited by 4 •
2019
This article describes a method to generate functional tumor antigen-specific induced pluripotent stem cell-derived CD8αβ+ single positive T cells using OP9/DLL1 co-culture system.
03:32
A Technique for the Generation of Antigen-Specific CAR T Cells
0 Views •
2025
This video demonstrates a technique for generating antigen-specific chimeric antigen receptor (CAR) T cells through retroviral transduction. Activated murine CD8+ T cells are added to a microwell plate coated with recombinant fibronectin fragments. Retroviral vectors containing transgenic RNA encoding an antigen-specific chimeric antigen receptor (CAR) are then introduced, and the plate is centrifuged to facilitate transduction. After incubation, the transduced cells express antigen-specific...
02:42
An In Vitro Assay to Evaluate the Anti-Tumor Activity of Tumor-Specific CAR T Cells
0 Views •
2025
This video demonstrates an in vitro assay to validate chimeric antigen receptor (CAR) T cell activity. B-cell lymphoma cells expressing CD19 antigen and cytoplasmic luciferase are co-cultured with CD19-specific CAR T cells. CAR binding to CD19 on a tumor induces the CAR T cells to release cytokines and toxins that cause tumor cell cytotoxicity. The CAR T cell activity is evaluated by quantifying the released cytokine and decreased luciferase-mediated bioluminescence in the tumor cells.
06:20
An Assay for Cell Cycle Analysis of Antigen-Specific CD8+ T Cells
0 Views •
2025
This video demonstrates an assay to analyze antigen-specific CD8+ T cells in different cell cycle stages. Fluorescently-labeled viable cells are selected using flow cytometry, and the cells in the different cell cycle stages are identified by their DNA content using antibodies against cell proliferation-associated nuclear protein and a nucleic acid stain.
FAQs
Tumor-derived peptide antigens must be displayed by major histocompatibility complex molecules for recognition by the T-cell receptor. This interaction initiates signaling pathways that can produce cytokines, promote target-cell killing, and coordinate additional immune responses. Consequently, antigen presentation acts as a key control point linking molecular recognition to measurable antitumor effector functions.
Specificity helps distinguish T cells that recognize cancer-related targets from responses with broader or less relevant reactivity. This distinction is important because tumor-specific or tumor-associated antigen recognition can guide treatment precision, while limiting damage to healthy tissues remains a central goal. Measuring specificity therefore informs both biological interpretation and therapeutic development.
Three important properties are antigen specificity, persistence, and functional activity. Specificity indicates what target the cells recognize, persistence reflects whether they remain available over time, and activity includes cytokine production or target-cell killing. Studying these features helps researchers compare candidate cell populations and identify characteristics associated with more effective adoptive cell therapy.
Naturally arising tumor antigen-specific T cells develop within patients as part of adaptive antitumor immunity. For adoptive cell therapy, researchers can instead isolate these cells, expand their numbers, and select populations with desired recognition or activity. The two settings differ in how the cells are obtained and prepared, while both depend on antigen-specific immune function.
A supported workflow includes isolating relevant T cells, expanding them to increase their numbers, and selecting cells with useful antigen recognition or functional characteristics. Researchers then evaluate properties such as specificity, persistence, and activity to support treatment development. This process is intended to enrich candidate populations rather than rely only on the cells present naturally in a patient.
They are studied when researchers need to evaluate antitumor immune responses, develop adoptive cell therapies, or identify biomarkers linked to treatment potential. Measurements of antigen specificity, persistence, and functional activity can help characterize candidate cell populations. These data also support efforts to improve treatment precision and understand why particular immune responses may be more useful.
Their defined antigen recognition provides a basis for directing immune activity toward cancer-related targets rather than relying on nonspecific responses. Researchers can use this feature to select or expand cell populations with suitable activity and assess whether they retain persistence. The resulting information supports strategies designed to strengthen antitumor effects while limiting injury to healthy tissues.